Related Experiment Videos
[Clinical evaluation of cefdinir in pediatric field]
K Mikuni1, Y Ishikawa, S Takahashi
1Department of Pediatrics, School of Medicine, Kyorin University.
Insights
Cefdinir (CFDN) demonstrated 100% clinical efficacy in treating pediatric infections, including respiratory tract infections. This new oral cephalosporin showed no adverse effects, making it a safe option for children.
Area of Science:
- Pediatric infectious diseases
- Clinical pharmacology
- Antimicrobial therapy
Background:
- Pediatric infections require effective and safe antimicrobial agents.
- Oral cephalosporins are frequently used for common childhood infections.
- Cefdinir (CFDN) is a third-generation oral cephalosporin with broad-spectrum activity.
Purpose of the Study:
- To evaluate the clinical efficacy and safety of cefdinir (CFDN) in children with mild to moderate infections.
- To assess the bacteriological eradication rates of common pathogens in pediatric infections treated with CFDN.
Main Methods:
- A clinical study involving 18 pediatric patients aged 2 years and 4 months to 11 years and 4 months.
- Patients were diagnosed with respiratory tract infections, impetigo, or balanoposthitis.
- Clinical and bacteriological outcomes were assessed following cefdinir treatment.
Main Results:
- 100% clinical efficacy was observed, with 11 patients showing excellent and 7 showing good responses.
- Bacteriological eradication was achieved in 64.3% (9/14) of clinical isolates.
- No adverse side effects or abnormal laboratory findings were reported during the study.
Conclusions:
- Cefdinir (CFDN) is a highly effective and well-tolerated oral antibiotic for treating mild to moderate pediatric infections.
- The drug's safety profile and high efficacy rate support its use in pediatric populations.
- CFDN represents a valuable therapeutic option for common childhood bacterial infections.
Abstract:
We studied the clinical efficacy of cefdinir (CFDN), a new oral cephalosporin, in 18 children with ages 2 years and 4 months to 11 years and 4 months with pediatric infections. The diagnoses consisted of respiratory tract infections in 15 cases, impetigo in 2 and balanoposthitis in 1. Clinical efficacies were excellent in 11 patients and good in 7, with an efficacy rate of 100%. Bacteriologically, 9 (64.3%) of the 14 strains of clinical isolates were eradicated. No side effects nor abnormal laboratory findings were observed. We have concluded that CFDN is a useful antibiotic for the treatment of mild to moderate pediatric infections.